Italian PM Matteo Renzi says to file resignation request later on MondayWorld December 05, 4:37
Moscow not seen as possible host of Eurovision 2017 song contest - mediaSociety & Culture December 04, 22:22
Et-Tell in Damascus Province fully controlled by Syrian governmentWorld December 04, 21:46
Mirziyoyev campaign office says he is winning presidential elections in UzbekistanWorld December 04, 21:40
Preliminary results of Uzbekistan’s presidential polls to be announced on December 5 - CECWorld December 04, 21:28
Putin expresses condolences over fatal road accident in Khanty-Mansyisk autonomous areaSociety & Culture December 04, 20:20
Emergencies ministry confirms death of 12 people in road accident near Khanty-MansyiskSociety & Culture December 04, 17:04
Fidel Castro buried in Santiago de CubaWorld December 04, 16:50
Cuban revolution in pictures: Early years of Fidel CastroWorld December 04, 16:49
BREA, Califonia and SEOUL, Korea, Nov. 13 /PRNewswire/ -- Beckman Coulter Diagnostics, a world leader in the IVD industry, and Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies, today announced a Molecular Diagnostic assay supply agreement. Under the agreement, Seegene will begin manufacturing reagents designed exclusively for Beckman Coulter's new sample-to-answer Molecular Diagnostics instrument, the VERIS MDx System*.
Richard Creager, senior vice president of the MDx Business Unit and chief scientific officer at Beckman Coulter said, "We're very excited to partner with Seegene and incorporate their novel and proprietary DPO, TOCE and MuDT technologies into our MDx solution. We expect to be able to quickly add to the menu we offer on VERIS with the Seegene Multiplex reagents that enable simultaneous and multiple detection and identification of various types of pathogens in a single test."
Seegene founder and CEO, Dr. Jong-Yoon Chun, said, "Our observation is that the VERIS system breaks new ground in enabling laboratories to perform MDx testing in the most efficient way possible. This partnership fully supports our promise to contribute to humanity by developing faster, more accurate and cost-effective innovative MDx systems."
As more diseases are discovered around the world, Seegene is taking the lead in developing new technology for accurate diagnosis. Seegene aims to create more opportunities for patients to start a new chapter of their lives by experiencing innovative products to increase the chance for their successful treatment. Seegene endlessly strives toward the new possibility of a world free of disease. With distributors in 57 countries and employees all around the world, Seegene strives to satisfy the varying demands of local customers by quickly listening and responding. Seegene's bold investment and endeavors in R&D allow launching numerous the world-leading products which are currently available in the market.
Beckman Coulter Diagnostics develops clinical diagnostic products that help advance and optimize the clinical laboratory. Beckman Coulter's instruments, systems and tests help streamline processes to enhance efficiency, reduce costs and speed the delivery of results. For nearly 80 years, Beckman Coulter has been a global leader devoted to providing solutions to laboratories of all sizes, offering a broad portfolio of chemistry, immunoassay, hematology, urinalysis, automation and information systems. Beckman Coulter is dedicated to advancing healthcare for every person and moving science, innovation and the lab forward. For more information, visit www.beckmancoulter.com.
*The VERIS system and VERIS human Cytomegalovirus (CMV) assay are CE cleared in Europe. The system is still in development for the United States; it is not available for in vitro diagnostic use in the United States.
Beckman Coulter, the stylized logo, and VERIS are trademarks of Beckman Coulter, Inc. and registered in the USTPO. DPO, TOCE and MuDT are trademarks of Seegene.
Constantine Theodoropulos Base Pair Group (USA)
Tel.: : +1-617-816-4637
Jennifer Kim Seegene, Inc. (Korea)
Mary Luthy Beckman Coulter Diagnostics
Tel.: : +1-714-961-6364